Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

EMA begins rolling review of Merck’s and Ridgeback’s COVID-19 pill molnupiravir

By Brian Buntz | October 26, 2021

Merck logoMerck (NYSE: MRK) and its partner Ridgeback Biotherapeutics has announced that the European Medicines Agency (EMA) has begun a rolling review for molnupiravir, the experimental antiviral that could be the first oral treatment for COVID-19 to hit the market.

Merck has also submitted emergency use authorization (EUA) paperwork related to the drug to FDA.

The company is also pursuing marketing authorization in other countries across the globe.

“This application to the EMA is another step in our efforts to bring molnupiravir forward to patients globally,” said Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, in a statement.

Interim data from the Phase 3 MOVe-OUT clinical trial found that the drug effectively reduced symptom progression in non-hospitalized patients with mild-to-moderate COVID-19. The patients in that study were deemed to have an elevated risk of developing severe COVID-19 or hospitalization.

Overall, the drug appeared to reduce the risk of hospitalization or death by roughly 50%.

The drug also appeared to be well tolerated, with side effects roughly even between drug and placebo groups.


Filed Under: Infectious Disease
Tagged With: Merck, Molnupiravir, Ridgeback Biotherapeutics
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

JYNNEOS vaccine
Jynneos vaccine: The best weapon against monkeypox?
Axcella
Axcella touts positive results from Phase 2a long COVID study
monkeypox
3 critical monkeypox vaccine questions 
Moderna in the Drug Discovery & Development Pharma 50
Moderna inks deal with US for up to 300M omicron boosters

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50